Chippenham - based company Alliance Pharma has reached an agreement with Sinclair Pharma over compensation in connection with the sales rights of Kelo - stretch , acquired by Alliance in December 2015 . A cash payment of £ ##5 m ( $ 6.2 m ) will be made in two phases , £ 4 m in 2017 and £ 1 m in 2018 , while Alliance will also relinquish all US rights to Flammacerium . Alliance plans to seek guidance from the UK regulatory authority later this year on registration of Flammacerium in the country .
Chippenham-based company Alliance Pharma has reached an agreement with Sinclair Pharma over compensation in connection with the sales shortfall of Kelo-stretch, acquired by Alliance in December 2015. A cash payment of £5m ($6.2m) will be made in two phases, £4m in 2017 and £1m in 2018, while Sinclair will also relinquish all US rights to Flammacerium. Alliance plans to seek guidance from the US regulatory authority later this year regarding registration of Flammacerium in the country.